首页|期刊导航|Cancer Innovation|Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer(2025 Edition)
Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer(2025 Edition)
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center The Society of Clinical Research on Oncology Medications of the China Anti-Cancer Association The Society of Onco-Pathology of the China Anti-Cancer Association Fei Ma Binghe Xu
Cancer Innovation2025，Vol.4Issue(3)：P.28-52,25.
Cancer Innovation2025，Vol.4Issue(3)：P.28-52,25.DOI:10.1002/cai2.70008
Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer(2025 Edition)
摘要
关键词
AKT inhibitor/breast cancer/expert consensus/hormone receptor/mTOR inhibitor/PI3K inhibitor分类
医药卫生引用本文复制引用
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer,The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center,The Society of Clinical Research on Oncology Medications of the China Anti-Cancer Association,The Society of Onco-Pathology of the China Anti-Cancer Association,Fei Ma,Binghe Xu..Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer(2025 Edition)[J].Cancer Innovation,2025,4(3):P.28-52,25.基金项目
the Major Collaborative Innovation Project,Medical and Health Science and Technology Innovation Initiative,Chinese Academy of Medical Sciences(Project No.2021‐I2M‐1‐014). （Project No.2021‐I2M‐1‐014）
